Psychedelic ETFs Back in the Spotlight

Psychedelic ETFs and Biotech and Genomics ETFs among Canada’s top weekly performers.

Eddie Barrak
 · 8/9/2022
diamonds

A psychedelic ETF reigned over Canada’s top-performing ETFs last week, driven by a positive stance by Morgan Stanley. Meanwhile, biotechnology and genomics-related ETFs benefit from strengthening select stocks.

Psychedelic ETF Reigns over this Week's Top Performers

The Horizons Psychedelic Stock Index ETF (PSYK) bested its Canadian exchange-traded funds, ranking first among the weekly top performers. PSYK has soared 17.27% during the first week of August as mainstream industry recognition continued apace. According to The Dales Report, the psychedelic sector has witnessed an upward trend since July 12th, 2022, when ‘How to Change Your Mind’ debuted on Netflix. Compass Pathways PLC, which happens to be the most significant holding of PSYK, was amongst the biggest beneficiaries of the trend, having risen around 61% in four weeks. Moreover, the company reported its financial results and business highlights, showing an increase in R&D expenditures and phase 3 program submission to the FDA. On another front, Counterpoint Global, Morgan Stanley’s investment management division in charge of understanding disruptive market opportunities, released a report focusing on psychedelics developments for medical purposes. The report pointed out Morgan Stanley’s positive stance on the psychedelics industry for the future. It predicts that the industry will grow to USD$6 trillion by 2030.   

ETFs in play:

Biotech and Genomics ETFs in the Green

Some healthcare tech stocks experienced strengthening recently, pushing some Biotech and Genomics exchange-traded funds higher over the week between August 1st and August 5th. The Emerge ARK Genomics & Biotech ETF USD (EAGB.U) and CAD (EAGB), and the iShares Genomics Immunology and Healthcare Index ETF (XDNA), jumped 11.32%, 11.11%, and 8.16%, respectively. The gains were driven mainly by overlapping stocks trading in the green. Most notably, Beam Therapeutics Inc (NASDAQ:BEAM) rose 7.80% over the week to reach USD$63.63 while Fate Therapeutics Inc (NASDAQ:FATE) surged almost 11.25% – from USD$30.04 to USD$33.42 – over the same period. Together, these two stocks represent 9.1% of Emerge ARK Genomics & Biotech ETF’s total portfolio and 9.73% of iShares Genomics Immunology and Healthcare Index ETF.  

ETFs in play:

Data for this article is as of August 5th, 2022.

Issuer insights

Partner content

Issuer Insights | Active Fixed Income ETFs

In the latest Issuer Insights episode from ETF Market Canada, Dave Andrews, VP & Senior Client Portfolio Manager at Franklin Templeton Fixed Income Group, explains why active management matters now, more than ever.

Sponsored by Franklin Templeton

Building Around the Core

Issuer Insights | Franklin Core Equity ETFs: How Systematic Strategies Answer Investor Needs

Franklin Templeton’s Michael Greenberg explains how a risk-controlled, multi-factor equity core can free up fee and risk budget for higher-conviction positions elsewhere in a portfolio.

Sponsored by Franklin Templeton

Issuer Insights | Beyond the Benchmark: A Smart Way to Build Your Core Portfolio

Issuer Insights | Beyond the Benchmark: A Smart Way to Build Your Core Portfolio

Fee pressure and concentrated markets are pushing advisors to rethink the core of client portfolios. In our latest piece, Franklin Templeton’s Michael Greenberg makes the case for a factor-based core that blends benchmark exposure with systematic alpha, and explains how to decide whether to replace, complement or consolidate existing positions.

Sponsored by Franklin Templeton

Issuer Insights | Moats Mater in 2026: Meet FDIV

Issuer Insights | Moats Mater in 2026: Meet FDIV

A closer look at FDIV’s three-pillar approach—quality, growth, and income—and how it can serve as a core or satellite allocation in U.S. equity portfolios.

Sponsored by Franklin Templeton

issuer Insights | 2026: Global Diversification Is In

Issuer Insights | 2026: Global Diversification Is In

Looking beyond North America may be the smart move for 2026. In our recent Issuer Insights episode from ETF Market Canada, Ahmed Farooq of Franklin Templeton Investments highlighted how international markets, driven by European infrastructure and defense spending and Asia’s AI boom, are outperforming the U.S.

Sponsored by Franklin Templeton

Alex Lee FLVI

Issuer Insights | FLVI and How Investors Can Tackle Volatility

In our latest episode of Issuer Insights, Alex Lee, Canadian Head of ETF Product Strategy at Franklin Templeton Investments, discusses how #investors are navigating uncertainty - from market volatility to global diversification trends.

Sponsored by Franklin Templeton

V1 - FMID Issuer Insights Thumbnail

Issuer Insights | Navigating Bond Markets with Active Fixed Income ETFs

Sponsored by Franklin Templeton

Isseur Insights - Volatility

Issuer Insights | Staying Resilient Through Market Volatility

Sponsored by Franklin Templeton

Issuer Insights | Franklin U.S. Mid Cap Multifactor Index ETF (FMID)

Issuer Insights | Franklin U.S. Mid Cap Multifactor Index ETF (FMID)

Sponsored by Franklin Templeton

Issuer Insights | Finding the Sweet Spot in Bond Investing

Issuer Insights: Finding the Sweet Spot in Bond Investing

Sponsored by Franklin Templeton

Issuer Insights | Franklin Canadian Ultra Short Term Bond Fund (FHIS)

Issuer Insights: Franklin Canadian Ultra Short Term Bond Fund (FHIS)

Sponsored by Franklin Templeton

Issuer Insights Thumbnail

Issuer Insights: Franklin Multi-Asset ETF Portfolio

Sponsored by Franklin Templeton

ETF Education Centre

CboeTrackinsight
The ETF Market Canada is brought to you by Cboe in partnership with Trackinsight SA who is providing all the data, analysis and editorial content on this site. Unless explicitly stated as such, any information that you receive is not real-time.

All content on the ETF Market Canada is for your general information use only, Cboe is not responsible for any use of content by you outside this scope. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by Cboe and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
diamonds
Get ETF updates by email

Never miss the latest Canadian ETF Investing news and updates